NEJM:阿奇霉素(azithromycin)并不增加青年和中老年人患者心血管事件死亡

2013-08-15 MedSci MedSci原创

以前研究认为阿齐霉素对心血管高风险人群,能够增加心血管死亡风险。但是在真实世界人群中缺乏研究。为此,一项大规模真实世界中的人群研究,刚刚发表在本期的新英格兰杂志上。这是一项18-64岁丹麦的国家级的历史队列研究,关联处方登记注册数据库,患者死亡原因,以及在1997至2010年间患者的一般情况等资料。评估了使用阿齐霉素达到110万疗程,与未使用抗生素的人群对照(1:1倾向得分匹配),另外,还与736

以前研究认为阿齐霉素对心血管高风险人群,能够增加心血管死亡风险。但是在真实世界人群中缺乏研究。为此,一项大规模真实世界中的人群研究。这是一项18-64岁丹麦的国家级的历史队列研究,关联处方登记注册数据库,患者死亡原因,以及在1997至2010年间患者的一般情况等资料。评估了使用阿齐霉素达到110万疗程,与未使用抗生素的人群对照(1:1倾向得分匹配),另外,还与736万人次使用penicillin V进行对比(也根据倾向得分匹配),观察心血管原因死亡。


结果发现使用阿齐霉素与不使用任何抗生素的人群心血管死亡风险显著增加(RR:2.85, 95CI:1.13 - 7.24).在阿齐霉素组有17例患者死亡,在penicillin V组有146例患者死亡(RR:0.93,95%CI:0.56-1.55)。阿齐霉素并不增加年青人和中老年患者的心血管死亡风险。

原始出处:

Svanström H, Pasternak B, Hviid A.Use of azithromycin and death from cardiovascular causes.N Engl J Med. 2013 May 2;368(18):1704-12.

Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S.Cardiovascular risks with azithromycin and other antibacterial drugs.N Engl J Med. 2013 May 2;368(18):1665-8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2014-03-29 kalseyzl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1923745, encodeId=003e1923e4507, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Mon Jun 09 11:22:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771291, encodeId=50831e7129109, content=<a href='/topic/show?id=9ced223904c' target=_blank style='color:#2F92EE;'>#中老年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22390, encryptionId=9ced223904c, topicName=中老年人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71df38244151, createdName=gjsgj, createdTime=Tue Aug 27 17:22:00 CST 2013, time=2013-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643319, encodeId=a469164331982, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Feb 03 08:22:00 CST 2014, time=2014-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714695, encodeId=9ca31e14695cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Wed May 07 07:22:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773453, encodeId=13871e7345322, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Mar 29 07:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274787, encodeId=81d712e478767, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 17 13:22:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-08-17 guihongzh

相关资讯

FDA审核阿奇霉素的心血管危险

      2012年5月17日,美国食品与药物管理局(FDA)发布通告,称其将要审核一项当日发表于《新英格兰医学杂志》[N Engl J Med,2012-05-17;366(20):1881-90.]的新研究,这项观察性研究纳入了接受为期5天阿奇霉素治疗的美国补助医疗保险(Medicaid)患者。结果显示,与接受阿莫西林、环丙沙星或根本不用抗生素治疗的患者相比,接

Lancet:阿奇霉素防止非囊性纤维化支气管扩张症病情恶化

研究者发现阿奇霉素(希舒美)有助于防止非囊性纤维化支气管扩张症(以下简称支扩症)患者病情的恶化。新西兰奥克兰市米德摩尔医院(Middlemore Hospital)的Conroy Wong博士和他的同事在8月18日的《柳叶刀》上报道了他们的新发现:服用阿奇霉素6个月的受试者较随机安慰剂组的受试者在基于事件的恶化风险上有62%的相对降低量(P<0.0001)。支扩症患者常伴随有气道炎症,慢性细

NEJM:阿奇霉素与心血管原因死亡风险增加无关

在基线高危患者中,阿奇霉素的使用与心血管原因的死亡危险升高相关。在未经选择的普通人群中,阿奇霉素是否引起同样的危险尚不清楚。丹麦哥本哈根市国家血清研究所流行病学研究科Henrik Svanstr?m博士等人展开了相关研究,他们发现在青年和中年人的普通人群中,阿奇霉素使用与心血管原因死亡危险升高无关。研究成果日前发表于国际权威杂志NEJM在线版。 研究人员以丹麦成年人(年龄18~64岁)为样本进行

AIM:克拉霉素或红霉素升高他汀药物毒性反应风险

  美国一项研究表明,在老年人群中,他汀类与克拉霉素或红霉素同时应用可升高他汀类药物的毒性反应风险。论文发表于《内科学年鉴》[Ann Intern Med 2013;158(12):869]。   此项基于人群的队列研究纳入了年龄大于65岁的他汀类持续应用者,并对同时应用克拉霉素(72591例)或红霉素(3267例)的受试者和同时应用阿奇霉素者(68478例)进行了

NEJM述评:阿奇霉素和其他抗菌药的心血管风险

根据IMS健康研究公司数据,2011年全美约4.3千万(约1/8人口)服用过门诊处方药中的大环内脂类抗生素阿奇霉素。鉴于其心血管疾病风险,这一年,我们在美国食品和药物管理局(FDA)重审了阿奇霉素及其他已批准的大环内酯类抗菌药的标签说明,从发表的研究报告及上市后监测报告来看,这种风险已变得相当明显。在重审的基础上,考虑其所致的QT间期延长和与之相关的尖端扭转型室速,FDA批准了对阿奇霉素标签说明的

Ann Intern Med:克拉霉素或红霉素升高他汀药物毒性反应风险

  美国一项研究表明,在老年人群中,他汀类与克拉霉素或红霉素同时应用可升高他汀类药物的毒性反应风险。论文发表于《内科学年鉴》。   此项基于人群的队列研究纳入了年龄大于65岁的他汀类持续应用者,并对同时应用克拉霉素(72591例)或红霉素(3267例)的受试者和同时应用阿奇霉素者(68478例)进行了比较。主要转归为抗生素处方开具30天内因横纹肌溶解而住院治疗。   结果显示,阿托伐他汀(